Summary by Futu AI
Kechi Pharmaceuticals-B announced its interim performance on June 30, 2024, showing unaudited comprehensive interim performance and comparative figures for the same period in 2023. The company has made progress in technology innovation, product pipeline, and business operations in the United States and China. Saikai Ze® has been approved by the National Medical Products Administration for listing and is used to treat relapsed or refractory multiple myeloma in adult patients. The company has signed a cooperation agreement with Huadong Medicine for the commercialization of Saikai Ze® in mainland China. As of July 31, 2024, Saikai Ze® has been included in insurance policies in nearly 20 provinces or cities and has received 52 orders. The company's other products, such as Surijiolon Saisolution and CT071, are also undergoing clinical trials. The company's revenue is approximately RMB 6 million, mainly from Saikai Ze®, with a gross profit of approximately RMB 2 million and a net loss of approximately RMB 352 million, a decrease of approximately RMB 52 million compared to the same period last year. The cash and bank balance is approximately RMB 1,653 million.